Healthcare / Medical DevicesNasdaqCM
$2.35
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-9.3M · quality 49.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$10M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-353.8%
↓Gross Margin
45.3%
↓Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
-22.7%
FCF CAGR
—
FCF margin
-860.1%
FCF / Net income
0.84x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.0M · net income $-10.4M · FCF $-8.8M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | $1.0M | $1.0M | $2.9M | $2.6M | $1.6M | $606000.00 | $594000.00 | $689000.00 | $95000.00 | $11.2M | $15.2M | $19.5M | $22.8M | $22.3M |
| Net Income | $-10.4M | $-10.4M | $-11.0M | $-8.3M | $-12.0M | $-9.3M | $-7.0M | $-4.8M | $-8.7M | $-9.3M | $-14.8M | $-23.9M | $-32.6M | $-8.3M |
| EPS | -6.16 | -6.16 | -15.19 | -624.47 | -60.81 | -39.91 | -1.08 | -5.69 | -76.73 | -3.13 | — | — | — | — |
| Gross Margin | 45.3% | 45.3% | 71.9% | 70.2% | 83.0% | 25.9% | 20.0% | 20.0% | 41.1% | 43.4% | 75.2% | 67.9% | 65.3% | 68.4% |
| Operating Margin | -1053.1% | -1053.1% | -486.6% | -508.5% | -726.1% | -1752.5% | -1431.6% | -957.0% | -13806.3% | -66.7% | -75.8% | -61.9% | -106.2% | -46.3% |
| Net Margin | -1018.1% | -1018.1% | -381.8% | -314.4% | -771.2% | -1536.1% | -1183.3% | -696.2% | -9107.4% | -83.1% | -97.0% | -122.9% | -143.1% | -37.1% |
| Balance Sheet | ||||||||||||||
| Debt/Equity | — | — | — | — | 0.06 | — | 0.01 | 0.00 | — | 0.54 | 1.06 | 1.51 | 0.44 | -0.12 |
| Cash Flow | ||||||||||||||
| Free Cash Flow | $-8.8M | $-8.8M | $-9.3M | $-14.6M | $-11.7M | $-13.9M | $-9.5M | $-6.6M | $-9.4M | $-4.7M | $-7.8M | $-9.8M | $-16.7M | — |
| Returns | ||||||||||||||
| ROE | -353.8% | -353.8% | -283.1% | -94.2% | -211.1% | -54.1% | -27.2% | -92.2% | -103.0% | -171.4% | -131.4% | -166.8% | -471.7% | 5.4% |
| Growth & Yield | ||||||||||||||
| Revenue Growth | -64.7% | -64.7% | 9.9% | 68.3% | 157.6% | 2.0% | -13.8% | 625.3% | -99.2% | -26.3% | -21.7% | -14.5% | 2.0% | — |
| EPS Growth | 59.4% | 59.4% | 97.6% | -926.9% | -52.4% | -3595.4% | 81.0% | 92.6% | -2351.4% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.